Dr. Martin Handfield Joins ONI BioPharma as Director, Research and Development

Oragenics, Inc. d/b/a ONI BioPharma Inc. (OTCBB:ORNI; Alternext Paris:ALONI), an American biopharmaceutical company, today announced that Dr. Martin Handfield has been appointed to the new position of Director, Research and Development. Prior to joining ONI BioPharma, Dr. Handfield was a tenured faculty member at the Center for Molecular Microbiology and Department of Oral Biology, University of Florida. Martin received his Ph.D. from Laval University in Canada and is a co-inventor of ONI BioPharma’s IVIAT platform technology that enables the rapid identification of novel and potentially important gene targets associated with the natural onset and progression of human infections. Mr. Stanley Stein, the Company’s President and Chief Executive Officer, stated, "We are delighted to have a scientist of Dr. Handfield’s stature join us. His technical and administrative experience will be of great value to the Company.”

As a reminder, quotations for ONI BioPharma’s shares are currently available on the Over-the-Counter (OTC) Bulletin Board under the symbol "ORNI”. Quotes, as well as the complete history of the Company, are available on the OTC-BB website www.otcbb.com, as well as on such financial websites as www.marketwatch.com, www.finance.yahoo.com, and www.moneycentral.msn.com. The OTC Bulletin Board is well suited to biotechnology and healthcare companies and offers an electronic trading platform for the Company’s North American investors. The Company expects to attract additional market makers to trade the stock on the OTC-BB. ONI BioPharma’s shares are also traded on Alternext. In December 2008, ONI BioPharma launched EvoraPlus™, the first of a line of products focused on oral health.

About ONI BioPharma

Oragenics, Inc. (d/b/a ONI BioPharma Inc.) is a biopharmaceutical company with a pipeline of unique proprietary technologies, some of which are being commercialized. The Company also has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, diagnostics, and oral health. The Company has developed platform technologies with respect to its products, thereby creating a potential pipeline of future products, which the Company expects to develop.

Forward-looking Statements

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect ONI BioPharma’s current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. ONI expressly disclaims any responsibility to update forward-looking statements and draws the attention of investors to the risk factors described in the Information Document.

This press release does not constitute the offering of any securities for sale. The Company’s securities may not be offered or sold absent registration under applicable securities laws or an exception from registration. Any public offering of the securities of the Company will be made by means of a prospectus that will contain detailed information about the offering and the Company.